Radar Telegram alerts Open Radar

A new drug for the treatment of pancreatic cancer has been approved for use in the European Union.

תרגם לעברית

DW Главное · · Source

🇺🇸 USA · Map

A new drug for the treatment of pancreatic cancer has been approved for use in the European Union.

The European Commission, through an expedited procedure, allowed the use of PassportReceive, developed in the USA, which was introduced in Chicago only in the summer of 2026. It took about 100 days for the drug to be approved. The drug can be used by adults who have undergone at least one course of chemotherapy, explained the European Commission in Brussels.

The action of Drachonresib (trade name - Rasonque) aims to slow down the growth of tumor cells. Studies have shown that the pills almost doubled the life expectancy of patients with metastatic pancreatic cancer whose bodies stopped responding to other types of chemotherapy. At the same time, draxonarsib does not cure cancer completely, but gives patients additional months of life and improves its quality.

Pancreatic cancer is considered one of the most dangerous, because it can be asymptomatic for a long time and is often discovered at a late stage - when there are already metastases. Nonspecific symptoms include weight loss, upper abdominal or back pain.

Every year in Europe, about 147 thousand people are diagnosed with pancreatic cancer, mostly in people over 70 years old. About 10% of patients remain alive five years after diagnosis, the Tagesschau TV channel cites data from the Robert Koch Institute (RKI).

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram